Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Modex completes patient enrollment in EpiDex phase II trial

Jan. 22, 2001

Wyeth-Ayerst seeks FDA approval of new indication of Alesse

Jan. 22, 2001

Meditech licenses Solaraze from SkyePharma

Jan. 22, 2001

Novogen receives grant for development of antiinflammatory drug

Jan. 19, 2001

Development of Fibrostat accelerated in Canada

Jan. 18, 2001

Arakis and Bioglan Pharma to jointly develop novel psoriasis treatment

Jan. 17, 2001

Atrisone advances to phase III testing in acne

Jan. 17, 2001

Results of phase III Metvix study show superiority to cryotherapy in treatment of AK

Jan. 17, 2001

New compounds acting on cell proliferation, differentiation for keratinization disorders

Jan. 15, 2001

Phase II trial begins with Idec's antipsoriatic antibody IDEC-114

Jan. 12, 2001

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...